Related Experiment Video
Updated: Dec 17, 2025
08:21
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
5.4K
Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A
Gaoxing Zhang1, Yongqiang Fan1,2, Yumin Qiu2
1Department of Cardiology, The Jiangmen Central Hospital, Jiangmen, China.
Advances in Therapy
|June 26, 2020
Summary
Allisartan isoproxil improved endothelial function and reduced vascular damage in patients with mild essential hypertension. This study highlights its potential as a promising treatment for hypertension management.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hypertension Research
Background:
- Allisartan isoproxil is a known angiotensin II type 1 receptor antagonist effective in lowering blood pressure and protecting organs.
- Its effects on endothelial function and vascular damage in hypertensive patients were previously uninvestigated.
Purpose of the Study:
- To evaluate the efficacy of allisartan isoproxil in improving endothelial function and vascular damage in patients with mild essential hypertension.
- To compare the effects of allisartan isoproxil plus lifestyle modification versus lifestyle modification alone.
Main Methods:
- A randomized controlled trial involving 72 patients with mild essential hypertension (BP 140/90–159/99 mmHg).
- Participants were assigned to either allisartan isoproxil (240 mg/day) plus lifestyle modification or lifestyle modification alone for 30 days.
- Endothelial function and vascular damage were assessed using flow-mediated dilation (FMD), brachial-ankle pulse wave velocity (baPWV), and endothelial microparticles (EMPs).
Main Results:
- The allisartan group showed a significant increase in FMD (p < 0.001) and significant reductions in EMPs (p < 0.001), baPWV (p < 0.001), systolic blood pressure (SBP, p < 0.001), and diastolic blood pressure (DBP, p < 0.001).
- The lifestyle modification group showed no significant change in FMD, EMPs, or baPWV, though SBP and DBP decreased.
- All measured indexes, except FMD, showed statistically significant differences between the allisartan and lifestyle modification groups (p < 0.05).
- After treatment, baPWV and EMPs in the allisartan group were comparable to healthy controls.
Conclusions:
- Allisartan isoproxil significantly improves endothelial function and reduces vascular damage in patients with mild essential hypertension.
- The drug demonstrates potential as a valuable therapeutic option for managing essential hypertension.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.2K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
790
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
790
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.1K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.1K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.1K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
333
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
333
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
362
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
362